Financials

  • Market Capitalization 1.29 B
  • Employee 125
  • Founded 2002
  • CEO N/A
  • Website www.dbv-technologies.com
  • Headquarter France
  • FIGI BBG0076D3T39
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-18.26
Rapporto prezzo/fatturato
474.74

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

Notizie